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Introduction {#sec005}
============

Platelet biology is influenced by gender \[[@pone.0225771.ref001]--[@pone.0225771.ref003]\]. Platelet count is higher in women, and a number of studies have highlighted that platelet activation is enhanced \[[@pone.0225771.ref004]--[@pone.0225771.ref006]\], due to a greater expression of many surface receptors \[[@pone.0225771.ref007], [@pone.0225771.ref008]\].

Women are more susceptible to aspirin resistance, with a rate of major coronary events and ischemic stroke under aspirin treatment that is not different with respect to controls \[[@pone.0225771.ref009], [@pone.0225771.ref010]\].

In patients under double anti-platelet therapy (DAPT) the interaction between gender and efficacy was absent \[[@pone.0225771.ref011], [@pone.0225771.ref012]\] or only demonstrated a trend towards a lower efficacy in women \[[@pone.0225771.ref013]\].

Most of the studies investigating gender-dependent differences in platelet function were based on platelet count only, obsolete tests (bleeding time), light-transmission aggregometry, optical aggregometry, or sophisticated laboratory tests. However, the recent randomized controlled trials investigating the efficacy of different P2Y~12~ inhibitors used point-of-care (POC) platelet function tests (PFT) to address platelet reactivity and high on-treatment platelet reactivity (HTPR) \[[@pone.0225771.ref014]--[@pone.0225771.ref016]\]. Overall, among the phenotypical factors leading to HTPR in patients under clopidogrel, gender female is considered \[[@pone.0225771.ref017]\].

A large study addressing gender-based differences in platelet function and platelet reactivity to P2Y~12~ inhibitors based on the currently available POC PFT is presently lacking. The present study is a large retrospective analysis of platelet count and function in cardiac surgery patients before surgery, using a POC PFT, and aimed to determine gender-based differences.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

The present study is a post-hoc analysis of three previous (two retrospective in 2012--2013 and one prospective in 2016--2017) studies performed at our institution between 2010 and 2017 \[[@pone.0225771.ref018]--[@pone.0225771.ref020]\]. In these studies, patients scheduled for cardiac operations were investigated with standard laboratory tests and POC PFT before surgery. Data from these studies were utilized to investigate the hypothesis that gender-based differences exist in platelet reactivity in patients with or without DAPT. The three studies were approved by the local Ethics committee that waived the need for an informed consent for the two retrospective studies (Ethics Committee Melegnano, approval number 2702, 15/2/2012) and requested a written informed consent for the prospective study (Ethics Committee San Raffaele Hospital, approval number 137/INT/2016). Data from the three studies were pooled together and differences in platelet count and function between women and male were analyzed separately for patients free from the effects of P2Y~12~ inhibitors or under full/residual effects of these drugs.

This work was supported by the IRCCS Policlinico San Donato which is a Clinical Research Hospital recognized and funded by the Italian Ministry of Health.

Patient population {#sec008}
------------------

The overall patient population included 760 adult cardiac surgery patients, of whom 440 were free from the effects of P2Y~12~ inhibitors (ticlopidine, clopidogrel, prasugrel or ticagrelor) and 320 were assessed within 6 days from P2Y~12~ inhibitors discontinuation.

The only exclusion criterion was the evidence of congenital platelet disease of any kind.

Data collection and definitions {#sec009}
-------------------------------

The following data were collected: demographics (age, gender, weight, height, and body mass index \[BMI\]); obesity (BMI \> 30 kg/m^2^); heart function details; presence of coronary artery disease; co-morbidities; use of P2Y~12~ inhibitors (with type of drug); days of discontinuation of these drugs; type of cardiac surgery; serum creatinine level (mg/dL); bilirubin level (mg/dL); hematocrit (%). For patients under DAPT, the standard dose was used (ticlopidine 250 mg twice a day; clopidogrel 75 mg/day, prasugrel 10 mg/day reduced to 5 mg if weight \< 60 kg; ticagrelor 90 mg twice a day).

Platelet function tests were performed at variable times before surgery, from 6 days to immediately before the induction of anesthesia, using a multiple-electrode aggregometry (MEA, Multiplate, Roche Diagnostics, Indianapolis, IN) and are explained in a dedicated section.

Platelet function tests {#sec010}
-----------------------

An amount of 3 mL of blood was drawn from a venous line and collected in hirudin-coated tubes provided by the manufacturer. Platelet aggregation testing on the MEA analyzer was performed as follows. Briefly, 300 μL of whole blood were added to an equal amount of preheated saline solution and platelet aggregation was tested after specific activation with adenosine diphosphate (ADP, ADPtest, 6.5 μM final concentration). P2Y~12~ receptors are inhibited by direct ADP receptor inhibitors (clopidogrel, ticlopidine, prasugrel and ticagrelor). Platelet aggregation was electronically measured for 6 minutes and expressed as units of area under the curve plotted over time (U). Normal reference range for ADPtest is 57--113 (U). HTPR was defined according to a recent consensus paper \[[@pone.0225771.ref021]\] as a MEA ADPtest value \> 46 U in patients under non-discontinued treatment with P2Y~12~ inhibitors. This cut-off value was increased to \> 60 U for a discontinuation time within 12and 24 hours before the PFT.

All the test were performed by a dedicated biologist (E.B.) in the hemostasis/coagulation laboratory of our institution.

Statistics {#sec011}
----------

For the purpose of this study, the dependent variable were (i) the platelet reactivity at the MEA ADPtest and (ii) the HTPR rate. The main independent variable was gender. Other potential determinants of the dependent variables were those listed in data collection and definitions section. Among them, platelet count was considered an important potential confounder of MEA ADPtest, and was included in adjusted models for platelet reactivity and HTPR rate.

Continuous variables are presented as median and interquartile range after verification of a non-normal distribution at the Kolmogorov-Smirnov test, and as number and percentage for categorical variables. Differences between continuous variables were tested with non-parametric tests. Differences in categorical variables were tested using a Pearson's chi square, producing relative risk and 95% confidence interval. Linear regression models were applied to adjust for potential confounders the relationship between gender and platelet function. Logistic regression models with dichotomous dependent variable were used to identify the independent variables and to adjust for potential confounders, producing odds ratio with 95% confidence interval. A P value \< 0.05 was considered significant for all the statistical tests. All the analyses were performed using computerized statistical packages (SPSS 13.0, IBM, Chicago, IL, GraphPad Prism 7.0, GraphPad Software, Inc., La Jolla, CA)

Results {#sec012}
=======

The general characteristics and the platelet count and function data are presented in [Table 1](#pone.0225771.t001){ref-type="table"}, separately for patients with or without residual effects of P2Y~12~ inhibitors. Apart from the normal anthropometric differences, within patients free from P2Y~12~ inhibitors women had a higher ejection fraction and NYHA class; a lower rate of stable coronary disease and diabetes; a lower hematocrit, serum creatinine value, and a higher serum bilirubin value. With respect to the platelet-related parameters, women had a significantly (P = 0.001) higher platelet count and a non-significantly (P = 0.085) higher platelet reactivity to ADP.

10.1371/journal.pone.0225771.t001

###### General characteristics and platelet-related variables of the patient population (N = 760).

![](pone.0225771.t001){#pone.0225771.t001g}

  ---------------------------------------------------------------------------- --------------------- ------------------- -------
  **Patients free from P2Y12 inhibitors (N = 440)**                                                                      
  **Variable**                                                                 **Women (N = 146)**   **Men (N = 294)**   **P**
  Age (years)                                                                  73 (61--78)           68 (59--74)         0.001
  Weight (kgs)                                                                 62 (56--70)           78 (70--88)         0.001
  Height (cms)                                                                 160 (156--165)        172 (168--178)      0.001
  Body mass index                                                              23.8 (21.4--27.3)     26 (23.9--29.3)     0.001
  Obesity                                                                      24 (16.4)             61 (20.7)           0.281
  Ejection fraction (%)                                                        55 (50--62)           55 (47--60)         0.019
  New York Heart Association class                                             0 (0--2)              0 (0--2)            0.005
  Stable coronary artery disease                                               42 (28.8)             149 (50.7)          0.001
  Unstable angina                                                              0 (0)                 0 (0)               N/A
  Congestive heart failure                                                     14 (9.6)              19 (6.5)            0.241
  Chronic obstructive pulmonary disease                                        12 (8.2)              18 (6.1)            0.411
  Previous cerebrovascular accident                                            6 (4.1)               9 (3.1)             0.568
  Diabetes on medication                                                       17 (11.6)             58 (19.7)           0.034
  Serum creatinine (mg/dL)                                                     1.0 (0.8--1.4)        1.2 (1.0--1.4)      0.001
  Serum bilirubin (mg/dL)                                                      0.5 (0.5--0.6)        0.5 (0.5--0.5)      0.039
  Hematocrit (%)                                                               38 (34--40)           42 (39--44)         0.001
  Platelet count (x 1,000 cells/μL)                                            211 (173--266)        191 (158--225)      0.001
  Platelet reactivity at ADP test (U)                                          58 (45--74)           56 (39--70)         0.085
  **Patients under or with residual effects of P2Y12 inhibitors (N = 320)**                                              
  **Variable**                                                                 **Women (N = 64)**    **Men (N = 256)**   **P**
  Age (years)                                                                  75 (66--79)           67 (60--74)         0.001
  Weight (kgs)                                                                 65 (55--76)           77 (70--83)         0.001
  Height (cms)                                                                 160 (155--165)        170 (166--175)      0.001
  Body mass index                                                              24.8 (22--31)         26.4 (24.2--28.4)   0.124
  Obesity                                                                      17 (26.6)             34 (13.3)           0.009
  Ejection fraction (%)                                                        50 (42--57)           53 (45--60)         0.148
  New York Heart Association class                                             0 (0--2)              0 (0--1)            0.982
  Stable coronary artery disease                                               39 (60.9)             188 (73.4)          0.049
  Unstable angina                                                              6 (10.9)              14 (5.9)            0.183
  Congestive heart failure                                                     4 (7.3)               18 (7.6)            0.941
  Chronic obstructive pulmonary disease                                        5 (9.1)               19 (8)              0.787
  Previous cerebrovascular accident                                            0 (0)                 4 (1.7)             0.333
  Diabetes on medication                                                       11 (20)               58 (24.4)           0.491
  Serum creatinine (mg/dL)                                                     0.9 (0.7--1.3)        1.0 (0.8--1.2)      0.233
  Serum bilirubin (mg/dL)                                                      0.5 (0.3--0.7)        0.55 (0.3--0.7)     0.135
  Hematocrit (%)                                                               37 (34--39)           39.4 (35.6--41.6)   0.001
  Platelet count (x 1,000 cells/μL)                                            220 (173--268)        189 (158--226)      0.001
  Platelet reactivity at ADP test (U)                                          41 (22--63)           32 (20--53)         0.148
  Platelet reactivity at ADP test (U)[°](#t001fn002){ref-type="table-fn"}      46 (26--65)           34 (22--56)         0.031
  Days of discontinuation                                                      2 (1--4.7)            2 (1--4)            0.712
  P2Y~12~ inhibitor                                                                                                      0.442
  Ticlopidine                                                                  7 (10.9)              20 (7.8)             
  Clopidogrel                                                                  52 (81.3)             216 (84.7)           
  Prasugrel                                                                    1 (1.6)               10 (3.9)             
  Ticagrelor                                                                   4 (6.3)               9 (3.5)              
  High on treatment platelet reactivity[°°](#t001fn003){ref-type="table-fn"}   7 (35)                15 (18.1)           0.097
  ---------------------------------------------------------------------------- --------------------- ------------------- -------

Data are median (interquartile range) or number (%). ADP: adenosindiphosphate

° Clopidogrel-treated patients only

°°No discontinuation or discontinuation time ≤ 24 hours before the test (N = 103, 20 women and 83 men).

Once adjusted for the platelet count, the ADP-dependent platelet reactivity lost even this non-significant trend for association with gender (regression coefficient 0.594, 95% confidence interval -3.87 to 4.96, P = 0.789), while platelet count was a significant determinant of platelet reactivity (regression coefficient 0.164, 95% confidence interval 0.132--0.195, P = 0.001).

Within patients under full or residual effects of P2Y~12~ inhibitors, women demonstrated a larger obesity rate, a lower rate of stable coronary disease and a lower hematocrit value.

The higher platelet count in women was confirmed within this subgroup. Platelets ADP reactivity was non-significantly (P = 0.148) higher in women, and the rate of HTPR was similar in women and men. When the analysis was restricted to clopidogrel-treated patients, the platelets ADP reactivity was significantly (P = 0.031) higher in women.

The values of ADP reactivity test as a function of the time of discontinuation are shown in [Fig 1](#pone.0225771.g001){ref-type="fig"}. This analysis is restricted to patients receiving clopidogrel within 6 days before the PFT. Within patients on full clopidogrel treatment or who discontinued clopidogrel within 24 hours before the PFT, the ADP-dependent reactivity of platelets was significantly (P = 0.014) higher in women (median 46 U, interquartile range 36--69) than in men (median 32 U, interquartile range 16--55). Once corrected for platelet count, gender female demonstrated a non-significant (P = 0.061) trend towards a higher platelet reactivity, while platelet count was significantly (P = 0.008) associated with a higher platelet reactivity. In this subgroup, there was a non-significant (P = 0.097) higher rate of HTPR in women (relative risk 2.44, 95% confidence interval 0.83--7.16).

![Platelet reactivity at the adenosine diphosphate (ADP) test in women and men, depending on the clopidogrel discontinuation time.\
IQR: interquartile range; MEA: multiple electrode aggregometry. Numbers within boxes are the number of subjects. The independent variables associated with HTPR are presented in [Table 2](#pone.0225771.t002){ref-type="table"}.](pone.0225771.g001){#pone.0225771.g001}

10.1371/journal.pone.0225771.t002

###### Factors associated with high on-treatment platelet reactivity (N = 103).

![](pone.0225771.t002){#pone.0225771.t002g}

  Item                                    HTPR (N = 22)     No HTPR (N = 81)    Relative risk (95% C.I.)   P
  --------------------------------------- ----------------- ------------------- -------------------------- -------
  Age (years)                             69 (62--77)       68 (60--75)         N/A                        0.435
  Gender female                           7 (31.8)          13 (16)             2.44 (0.83--7.16)          0.097
  Weight (kgs)                            76 (69--85)       75 (69--83)         N/A                        0.832
  Height (cms)                            160 (160--171)    170 (165--175)      N/A                        0.017
  Body mass index                         27.5 (23.7--31)   26.0 (23.8--28.1)   N/A                        0.288
  Obesity                                 6 (27.3)          11 (13.6)           2.38 (0.77--7.41)          0.125
  Ejection fraction (%)                   51 (40--57)       53 (45--60)         N/A                        0.674
  New York Heart Association class        0 (0--0)          0 (0--0)            N/A                        0.551
  Stable coronary artery disease          14 (63.6)         49 (60.5)           1.14 (0.43--3.03)          0.789
  Unstable angina                         4 (21.1)          4 (5.4)             4.67 (1.05--20.8)          0.030
  Congestive heart failure                1 (5.3)           5 (6.8)             0.77 (0.08--6.98)          0.813
  Chronic obstructive pulmonary disease   5 (26.3)          3 (4.1)             8.45 (1.81--39.5)          0.002
  Previous cerebrovascular accident       0 (0)             1 (1.4)             N/A                        0.610
  Diabetes on medication                  5 (26.3)          13 (17.6)           1.68 (0.51--5.47)          0.389
  Serum creatinine (mg/dL)                0.9 (0.8--1.1)    1.0 (0.8--1.1)      N/A                        0.711
  Serum bilirubin (mg/dL)                 0.6 (0.4--0.6)    0.6 (0.5--0.7)      N/A                        0.367
  Hematocrit (%)                          38.5 (32--40)     37.6 (34.3-4o)      N/A                        0.454
  Platelet count (x 1,000 cells/μL)       234 (186--280)    193 (154--235)      N/A                        0.027

Data are median (interquartile range) or number (%). N/A: not applicable.

Factors with a P value \< 0.1 were included in a multivariable analysis: for this purpose, continuous variables were dichotomized according to the median value. Within this model, factors independently associated with HTPR were unstable angina (odds ratio 6.0, 95% confidence interval 1.16--31, P = 0.033) and chronic obstructive pulmonary disease (odds ratio 7.2, 95% confidence interval 1.42--36, P = 0.017). Gender female was not independently associated with HTPR (odds ratio 2.14, 95% confidence interval 0.58--7.91, P = 0.253). A second model inclusive of gender female and platelet count only yielded an odds ratio for HTPR of 2.40 (95% confidence interval 0.80--7.20, P = 0.118).

The patient population was divided into four classes depending on gender and platelet count below or above the value of 200,000 cells/μL, that corresponds to the median value in the overall population ([Fig 2](#pone.0225771.g002){ref-type="fig"}). Female patients with a platelet count ≥ 200,000 cells/μL had the higher rate of HTPR (45.5%) with a significant (P = 0.023) difference with respect to males with a platelet count \< 200,000 cells/μL (11.9%), with a relative risk of 6.2 (95% confidence interval 1.4--29).

![High-on-treatment platelet reactivity (HTPR) in women and men under full clopidogrel effects, as a function of platelet count.\
PLT: platelet.](pone.0225771.g002){#pone.0225771.g002}

Discussion {#sec013}
==========

The main results of the present study may be summarized as follows: (i) in patients free from the effects of P2Y~12~ inhibitors, gender female is associated with a higher platelet count but not with a higher ADP-dependent platelet reactivity; (ii) in patients under full or residual effects of P2Y~12~ inhibitors of any kind, the ADP-dependent platelet reactivity was not significantly different between women and men; and (iii) in patients under full or residual effects of clopidogrel, the ADP-dependent platelet reactivity was significantly higher in women, especially in those who discontinued the drug within 24 hours before the test; however, only a trend remained after correction for platelet count; (iv) in patients who discontinued the P2Y~12~ inhibitors within 24 hours before the PFT, after correction for the potential confounders, the risk of HTPR was double in women vs. men, however without reaching a statistical significance. A combination of gender female and platelet count ≥ 200,000 cells/μL yielded a high risk of HTPR (45%).

Overall, our study seems to confirm a general trend towards a higher ADP-dependent platelet reactivity in women treated with P2Y~12~ inhibitors and namely with clopidogrel, however raising the possibility that this finding is dependent on differences in platelet count rather than function. Multiple-electrode aggregometry is based on the ability of platelets to aggregate on electrical filaments and hence to increase the electrical impedance. The increase in electrical impedance is not only dependent on the quality of platelet aggregation, but even on the quantity of platelets involved in the process. Previous studies have highlighted that the results of MEA have a positive association with platelet count, regardless of platelet count value \[[@pone.0225771.ref022]\]. A high platelet count has been already identified as a factor leading to HTPR \[[@pone.0225771.ref017], [@pone.0225771.ref018]\]. Other point-of-care tests of platelet function may have different associations with platelet count, but it reasonable to hypothesize that thrombocytosis affects platelet function measurements.

Even considering the confounding effect of higher platelet counts, a signal towards a higher rate of HTPR in women remains: after correction for platelet count, the odds ratio for HTPR is more than double in females, lacking statistical significance due to the relatively low sample size (103 patients). The combination of gender female and a high platelet count carries a risk for HTPR that is largely higher than what reported in the existing Literature \[[@pone.0225771.ref017],[@pone.0225771.ref018], [@pone.0225771.ref021]\].

Data on the role of gender in the determinism of HTPR are presently scarce. A cohort study on 846 treated with prasugrel or clopidogrel identified gender as a covariate affecting platelet inhibition in a linear mixed-effect model comparing the maximum platelet aggregation and the inhibition of platelet aggregation between treatments over time points \[[@pone.0225771.ref023]\]. A recent Danish study on stroke patients treated with clopidogrel reports that patients with HTPR were 46% females vs. 39% in non-HTPR patients \[[@pone.0225771.ref024]\]. This difference is larger in a recent study where gender female was found in 29% of HTPR patients vs. 15% in non-HTPR patients \[[@pone.0225771.ref025]\].

P2Y~12~ inhibitors commonly used for DAPT belong to thienopyridines (ticlopidine, clopidogrel, prasugrel) which irreversibly block the ADP receptor), or cyclopentyl triazolopyrimidines, which exert a reversible inhibition (ticagrelor). Cilostazol is not used in coronary patients. HTPR has been described in about 25% of patients treated with clopidogrel \[[@pone.0225771.ref018]\], 10% of patients treated with prasugrel, and 2% in patients treated with ticagrelor \[[@pone.0225771.ref026]\]. Other differences among these drugs include a more rapid onset of action for prasugrel and ticagrelor vs. clopidogrel \[[@pone.0225771.ref027]\].

Studies investigating the effects of prasugrel and ticagrelor failed to detect gender-related differences in outcomes \[[@pone.0225771.ref011],[@pone.0225771.ref012]\]. In these studies, the prevalence of gender female was between 25% and 28%. However, even if no differences in outcomes have been demonstrated, there are evidences that coronary patients under DAPT have different gender-based platelet reactivity and HTPR rate. In a recent study, Jastrszebka and associates found that women treated with a combination of aspirin and clopidogrel had a higher residual platelet reactivity than men, and a higher HTPR \[[@pone.0225771.ref028]\].

The physiological basis for a higher platelet reactivity in women, apart from their larger platelet count, has been hypothesized in previous studies. Platelets have estrogen receptors that inhibits platelet activation in pre-menopausal women \[[@pone.0225771.ref029]\]. This effect is lost in post-menopausal women (the large majority of our patient population). Additionally, estrogens are involved in prostacyclines synthesis and nitric oxide bioavalability \[[@pone.0225771.ref030]\], both factors blunting platelet aggregation. In pre-menopausal women, estrogen levels fluctuations may result in different levels of platelet reactivity.

As clopidogrel has to be metabolized by cytochrome P (CYP) enzymes, it is possible that there is an estrogen-dependent effect on CYP activity. Actually, there is an estrogen-dependent effect on cytochrome P450 3A (CYP3A) subfamily: in the endometrium, CYP3A4 and CYP3A43 are down-regulated by estrogen \[[@pone.0225771.ref031]\]. However, polymorphisms of CYP3A4 were not associated with treatment resistance when compared to responders to clopidogrel therapy \[[@pone.0225771.ref032]\].

In a study population similar to our study (coronary patients with stable angina) \[[@pone.0225771.ref028]\], the authors could find that in gender female the higher platelet reactivity while on DAPT with clopidogrel was associated with a pro-inflammatory profile, with higher levels of C-reactive protein and leukocytes.

There are limitations in our study. The first is the retrospective nature which did not allow us to address some possible confounders, like smoking habit. The second is the relatively low sample size with consequent no-significance of some potentially relevant trends. Finally, the great majority of our patients was treated with clopidogrel, which is a drug with a considerable HTPR rate. It is possible that the results differ if tested in patients under P2Y~12~ inhibitors with a lower rate of HTPR (prasugrel or tcagrelor).

Given these limitations, our study highlights that the subset of women with a high platelet count seems particularly susceptible to HTPR, at a rate (45%) larger than the expected (25% from the existing literature). This finding generates the hypothesis that this segment of patients, when requiring P2Y~12~ inhibitors, could potentially benefit from larger doses or, more reasonably, be directly treated with drugs carrying the lower risk of HTPR (ticagrelor). Association with oral anti-factor Xa drugs could be an additional option in patients requiring a prophylaxis of thrombotic events (atrial fibrillation). Further studies in these directions are warranted.
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